Clinical Trial Update: Study to Evaluate Fatigue in Participants With Relapsing Remitting Multiple Sclerosis When Treated With Dimethyl Fumarate [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial evaluating fatigue in people with relapsing-remitting multiple sclerosis treated with dimethyl fumarate has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis
• Relapsing-remitting Multiple Sclerosis

Drugs mentioned

• Dimethyl fumarate (Dimethyl fumarate)

Snippet

Sponsor: Biogen | Conditions: Relapsing-Remitting Multiple Sclerosis, Multiple Sclerosis | Phase 4 | Status: WITHDRAWN